Securities Code: 300289
Securities Abbreviation: Lideman
Announcement Number: 2026-043
Beijing Lideman Biochemical Co., Ltd.
Announcement on the Progress of Planning a Major Asset Restructuring
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
I. Basic Situation of This Major Asset Restructuring
Beijing Lideman Biochemical Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") plans to acquire a 61.50% stake in Beijing Sinopharm Xiangrui Biological Products Co., Ltd. (hereinafter referred to as the "Target Company") held by part of its shareholders through cash payment (hereinafter referred to as the "Transaction"). Before this transaction, the Company held no shares in the Target Company. After the transaction, the Company will obtain control of the Target Company, and the Target Company will become a controlling subsidiary of the Company. This transaction constitutes a major asset restructuring as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies." This transaction does not involve the issuance of shares by the Listed Company, does not constitute a related-party transaction, and will not lead to a change in the Company's control.
Due to the expiration of financial data and changes in the policy environment, the parties to the transaction have jointly agreed to adjust the transaction plan. For details, please refer to the "Announcement on the Adjustment of the Transaction Plan Not Constituting a Major Adjustment to the Restructuring Plan" (Announcement Number: 2026-036) disclosed by the Company on the Juchao Information Network (https://www.cninfo.com.cn) and other relevant announcements.
II. Disclosure of This Major Asset Restructuring
On July 30, 2025, the Company, the Target Company, a shareholder of the Target Company, Shanghai Baijiahui Investment Management Co., Ltd. (renamed "Hainan Baimai Investment Co., Ltd." on December 24, 2025), Hainan Sinopharm Baijiahui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) signed the "Investment Framework Agreement" regarding the matters related to this transaction. For details, please refer to the "Notice Announcement on the Planning of a Major Asset Restructuring and Signing of the Investment Framework Agreement" (Announcement Number: 2025-029) disclosed by the Company on the Juchao Information Network (https://www.cninfo.com.cn) on July 30, 2025.